A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma

A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma

The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant therapeutic b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational cancer research 2022-01, Vol.11 (1), p.99-112
Hauptverfasser: Yan, Leye, Lin, Junqing, Ke, Kun, Wu, Zhengzhong, Huang, Jingyao, Huang, Ning, Yang, Weizhu
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 112
container_issue 1
container_start_page 99
container_title Translational cancer research
container_volume 11
creator Yan, Leye
Lin, Junqing
Ke, Kun
Wu, Zhengzhong
Huang, Jingyao
Huang, Ning
Yang, Weizhu
description The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant therapeutic benefit for advanced HCC compared with sorafenib. We systematically evaluated and compared the efficacy and safety of hepatic arterial infusion chemotherapy and sorafenib for advanced HCC. A systematic search of PubMed, Embase, Web of Science and the Cochrane Library up to December 31, 2020 was conducted. Study outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects. The hazard ratio and odds ratio with 95% confidence intervals (CI) were used to measure the pooled effect. Eighteen retrospective or prospective cohort studies and one prospective controlled study were included, with 1,339 patients treated with hepatic arterial infusion chemotherapy (HAIC) and 1,060 patients treated with sorafenib. We found that hepatic arterial infusion chemotherapy was superior to sorafenib in terms of OS [hazard ratio (HR): 0.66, 95% CI: 0.46-0.95, P=0.027], PFS (HR: 0.55, 95% CI: 0.44-0.69, P
doi_str_mv 10.21037/tcr-21-1839
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8841468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2637585694</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-647917404296372f0dd4416bb35ed50a9dbb2e67a1bd20ec2662504c06681a733</originalsourceid><addsrcrecordid>eNpVkc1r3TAQxEVpaEKSW89Fxx7qVF-W5UshhLQNBHpJoDexltZ5KrbkSnLg_fd18tLQnnZgf8zOMoS85-xCcCa7z9XlRvCGG9m_ISdC8L7Rhsm3z9o0utM_j8l5Kb8YY4Jzo5h-R45lKzQ3xpyQeklnrNBAhGlfQqEuzQvkEB_oDheowVHIFXOAiYY4riWkSN0O51R3mGHZU4ielpRhxBgGOqZMwT9CdOgPDsnhNK0TZOoguxDTDGfkaISp4PnLPCX3X6_vrr43tz--3Vxd3jZOGlUbrbqed4op0WvZiZF5rxTXwyBb9C2D3g-DQN0BH7xg6ITWomXKMa0Nh07KU_Ll4Lusw4zeYawZJrvkMEPe2wTB_r-JYWcf0qM1RnGlzWbw8cUgp98rlmrnUJ7-gYhpLVZsuVrT6l5t6KcD6nIqJeP4eoYz-9yV3bralH3qasM__BvtFf7bjPwDwbKSjw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2637585694</pqid></control><display><type>article</type><title>A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Yan, Leye ; Lin, Junqing ; Ke, Kun ; Wu, Zhengzhong ; Huang, Jingyao ; Huang, Ning ; Yang, Weizhu</creator><creatorcontrib>Yan, Leye ; Lin, Junqing ; Ke, Kun ; Wu, Zhengzhong ; Huang, Jingyao ; Huang, Ning ; Yang, Weizhu</creatorcontrib><description>The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant therapeutic benefit for advanced HCC compared with sorafenib. We systematically evaluated and compared the efficacy and safety of hepatic arterial infusion chemotherapy and sorafenib for advanced HCC. A systematic search of PubMed, Embase, Web of Science and the Cochrane Library up to December 31, 2020 was conducted. Study outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects. The hazard ratio and odds ratio with 95% confidence intervals (CI) were used to measure the pooled effect. Eighteen retrospective or prospective cohort studies and one prospective controlled study were included, with 1,339 patients treated with hepatic arterial infusion chemotherapy (HAIC) and 1,060 patients treated with sorafenib. We found that hepatic arterial infusion chemotherapy was superior to sorafenib in terms of OS [hazard ratio (HR): 0.66, 95% CI: 0.46-0.95, P=0.027], PFS (HR: 0.55, 95% CI: 0.44-0.69, P&lt;0.001), ORR [assessed using Response Evaluation Criteria in Solid Tumors (RECIST): OR: 9.02, 95% CI: 6.01-13.53, P&lt;0.001; assessed using modified RECIST: odds ratio (OR): 3.71, 95% CI: 1.92-7.16, P&lt;0.001], and DCR (assessed using RECIST: OR: 2.31, 95% CI: 1.40-3.83, P=0.001; assessed by modified RECIST: OR: 2.28, 95% CI: 1.22-4.28, P=0.01). Dermatological adverse effects and hypertension were significantly higher in the sorafenib group for all grades of adverse effects. However, regarding severe adverse effects, hepatic arterial infusion chemotherapy was associated with more frequent leukocytopenia and thrombocytopenia. Hepatic arterial infusion chemotherapy demonstrated favorable efficacy and safety for advanced HCC compared with sorafenib and should be recommended for suitable patients with advanced HCC.</description><identifier>ISSN: 2218-676X</identifier><identifier>EISSN: 2219-6803</identifier><identifier>DOI: 10.21037/tcr-21-1839</identifier><identifier>PMID: 35261888</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Translational cancer research, 2022-01, Vol.11 (1), p.99-112</ispartof><rights>2022 Translational Cancer Research. All rights reserved.</rights><rights>2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-647917404296372f0dd4416bb35ed50a9dbb2e67a1bd20ec2662504c06681a733</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841468/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841468/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35261888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yan, Leye</creatorcontrib><creatorcontrib>Lin, Junqing</creatorcontrib><creatorcontrib>Ke, Kun</creatorcontrib><creatorcontrib>Wu, Zhengzhong</creatorcontrib><creatorcontrib>Huang, Jingyao</creatorcontrib><creatorcontrib>Huang, Ning</creatorcontrib><creatorcontrib>Yang, Weizhu</creatorcontrib><title>A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma</title><title>Translational cancer research</title><addtitle>Transl Cancer Res</addtitle><description>The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant therapeutic benefit for advanced HCC compared with sorafenib. We systematically evaluated and compared the efficacy and safety of hepatic arterial infusion chemotherapy and sorafenib for advanced HCC. A systematic search of PubMed, Embase, Web of Science and the Cochrane Library up to December 31, 2020 was conducted. Study outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects. The hazard ratio and odds ratio with 95% confidence intervals (CI) were used to measure the pooled effect. Eighteen retrospective or prospective cohort studies and one prospective controlled study were included, with 1,339 patients treated with hepatic arterial infusion chemotherapy (HAIC) and 1,060 patients treated with sorafenib. We found that hepatic arterial infusion chemotherapy was superior to sorafenib in terms of OS [hazard ratio (HR): 0.66, 95% CI: 0.46-0.95, P=0.027], PFS (HR: 0.55, 95% CI: 0.44-0.69, P&lt;0.001), ORR [assessed using Response Evaluation Criteria in Solid Tumors (RECIST): OR: 9.02, 95% CI: 6.01-13.53, P&lt;0.001; assessed using modified RECIST: odds ratio (OR): 3.71, 95% CI: 1.92-7.16, P&lt;0.001], and DCR (assessed using RECIST: OR: 2.31, 95% CI: 1.40-3.83, P=0.001; assessed by modified RECIST: OR: 2.28, 95% CI: 1.22-4.28, P=0.01). Dermatological adverse effects and hypertension were significantly higher in the sorafenib group for all grades of adverse effects. However, regarding severe adverse effects, hepatic arterial infusion chemotherapy was associated with more frequent leukocytopenia and thrombocytopenia. Hepatic arterial infusion chemotherapy demonstrated favorable efficacy and safety for advanced HCC compared with sorafenib and should be recommended for suitable patients with advanced HCC.</description><subject>Original</subject><issn>2218-676X</issn><issn>2219-6803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkc1r3TAQxEVpaEKSW89Fxx7qVF-W5UshhLQNBHpJoDexltZ5KrbkSnLg_fd18tLQnnZgf8zOMoS85-xCcCa7z9XlRvCGG9m_ISdC8L7Rhsm3z9o0utM_j8l5Kb8YY4Jzo5h-R45lKzQ3xpyQeklnrNBAhGlfQqEuzQvkEB_oDheowVHIFXOAiYY4riWkSN0O51R3mGHZU4ielpRhxBgGOqZMwT9CdOgPDsnhNK0TZOoguxDTDGfkaISp4PnLPCX3X6_vrr43tz--3Vxd3jZOGlUbrbqed4op0WvZiZF5rxTXwyBb9C2D3g-DQN0BH7xg6ITWomXKMa0Nh07KU_Ll4Lusw4zeYawZJrvkMEPe2wTB_r-JYWcf0qM1RnGlzWbw8cUgp98rlmrnUJ7-gYhpLVZsuVrT6l5t6KcD6nIqJeP4eoYz-9yV3bralH3qasM__BvtFf7bjPwDwbKSjw</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Yan, Leye</creator><creator>Lin, Junqing</creator><creator>Ke, Kun</creator><creator>Wu, Zhengzhong</creator><creator>Huang, Jingyao</creator><creator>Huang, Ning</creator><creator>Yang, Weizhu</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202201</creationdate><title>A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma</title><author>Yan, Leye ; Lin, Junqing ; Ke, Kun ; Wu, Zhengzhong ; Huang, Jingyao ; Huang, Ning ; Yang, Weizhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-647917404296372f0dd4416bb35ed50a9dbb2e67a1bd20ec2662504c06681a733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Yan, Leye</creatorcontrib><creatorcontrib>Lin, Junqing</creatorcontrib><creatorcontrib>Ke, Kun</creatorcontrib><creatorcontrib>Wu, Zhengzhong</creatorcontrib><creatorcontrib>Huang, Jingyao</creatorcontrib><creatorcontrib>Huang, Ning</creatorcontrib><creatorcontrib>Yang, Weizhu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Leye</au><au>Lin, Junqing</au><au>Ke, Kun</au><au>Wu, Zhengzhong</au><au>Huang, Jingyao</au><au>Huang, Ning</au><au>Yang, Weizhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma</atitle><jtitle>Translational cancer research</jtitle><addtitle>Transl Cancer Res</addtitle><date>2022-01</date><risdate>2022</risdate><volume>11</volume><issue>1</issue><spage>99</spage><epage>112</epage><pages>99-112</pages><issn>2218-676X</issn><eissn>2219-6803</eissn><abstract>The majority of patients with hepatocellular carcinoma (HCC) are diagnosed in an advanced stage. Although sorafenib is recommended as the standard treatment for advanced HCC, its efficacy is limited. In some studies, hepatic arterial infusion chemotherapy has demonstrated a significant therapeutic benefit for advanced HCC compared with sorafenib. We systematically evaluated and compared the efficacy and safety of hepatic arterial infusion chemotherapy and sorafenib for advanced HCC. A systematic search of PubMed, Embase, Web of Science and the Cochrane Library up to December 31, 2020 was conducted. Study outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse effects. The hazard ratio and odds ratio with 95% confidence intervals (CI) were used to measure the pooled effect. Eighteen retrospective or prospective cohort studies and one prospective controlled study were included, with 1,339 patients treated with hepatic arterial infusion chemotherapy (HAIC) and 1,060 patients treated with sorafenib. We found that hepatic arterial infusion chemotherapy was superior to sorafenib in terms of OS [hazard ratio (HR): 0.66, 95% CI: 0.46-0.95, P=0.027], PFS (HR: 0.55, 95% CI: 0.44-0.69, P&lt;0.001), ORR [assessed using Response Evaluation Criteria in Solid Tumors (RECIST): OR: 9.02, 95% CI: 6.01-13.53, P&lt;0.001; assessed using modified RECIST: odds ratio (OR): 3.71, 95% CI: 1.92-7.16, P&lt;0.001], and DCR (assessed using RECIST: OR: 2.31, 95% CI: 1.40-3.83, P=0.001; assessed by modified RECIST: OR: 2.28, 95% CI: 1.22-4.28, P=0.01). Dermatological adverse effects and hypertension were significantly higher in the sorafenib group for all grades of adverse effects. However, regarding severe adverse effects, hepatic arterial infusion chemotherapy was associated with more frequent leukocytopenia and thrombocytopenia. Hepatic arterial infusion chemotherapy demonstrated favorable efficacy and safety for advanced HCC compared with sorafenib and should be recommended for suitable patients with advanced HCC.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>35261888</pmid><doi>10.21037/tcr-21-1839</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2218-676X
ispartof Translational cancer research, 2022-01, Vol.11 (1), p.99-112
issn 2218-676X
2219-6803
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8841468
source EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
subjects Original
title A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A19%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20meta-analysis%20comparing%20hepatic%20arterial%20infusion%20chemotherapy%20and%20sorafenib%20for%20advanced%20hepatocellular%20carcinoma&rft.jtitle=Translational%20cancer%20research&rft.au=Yan,%20Leye&rft.date=2022-01&rft.volume=11&rft.issue=1&rft.spage=99&rft.epage=112&rft.pages=99-112&rft.issn=2218-676X&rft.eissn=2219-6803&rft_id=info:doi/10.21037/tcr-21-1839&rft_dat=%3Cproquest_pubme%3E2637585694%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2637585694&rft_id=info:pmid/35261888&rfr_iscdi=true